{"id":"https://openalex.org/W7223953262","doi":"https://doi.org/10.21873/anticanres.18458","title":"Association Between Proton Pump Inhibitor Use and Febrile Neutropenia During R-CHOP Therapy in Patients With Non-Hodgkin Lymphoma","display_name":"Association Between Proton Pump Inhibitor Use and Febrile Neutropenia During R-CHOP Therapy in Patients With Non-Hodgkin Lymphoma","publication_year":2026,"publication_date":"2026-10-27","ids":{"openalex":"https://openalex.org/W7223953262","doi":"https://doi.org/10.21873/anticanres.18458","pmid":"https://pubmed.ncbi.nlm.nih.gov/42946406"},"language":"en","primary_location":{"id":"doi:10.21873/anticanres.18458","doi":"https://doi.org/10.21873/anticanres.18458","is_oa":false,"landing_page_url":"https://doi.org/10.21873/anticanres.18458","pdf_url":null,"source":{"id":"https://openalex.org/S157347057","display_name":"Anticancer Research","issn_l":"0250-7005","issn":["0250-7005","1791-7530"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-d","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-3","vabb-shw"],"host_organization":"https://openalex.org/P4320800545","host_organization_name":"International Institute of Anticancer Research (IIAR) Conferences 1997. Athens, Greece. Abstracts","host_organization_lineage":["https://openalex.org/P4320800545"],"host_organization_lineage_names":["International Institute of Anticancer Research (IIAR) Conferences 1997. Athens, Greece. Abstracts"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Anticancer Research","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5057218448","display_name":"Masahito Shibano","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I167598709","display_name":"Osaka Ohtani University","ror":"https://ror.org/01jtn9895","country_code":"JP","type":"education","lineage":["https://openalex.org/I167598709"]},{"id":"https://openalex.org/I4387152983","display_name":"Osaka Metropolitan University","ror":"https://ror.org/01hvx5h04","country_code":"JP","type":"education","lineage":["https://openalex.org/I4387152983"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"MASAHITO SHIBANO","raw_affiliation_strings":["Department of Pharmacy, Osaka Metropolitan University Hospital, Osaka, Japan","Faculty of Pharmacy, Osaka Ohtani University, Osaka, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pharmacy, Osaka Metropolitan University Hospital, Osaka, Japan","institution_ids":["https://openalex.org/I4387152983"]},{"raw_affiliation_string":"Faculty of Pharmacy, Osaka Ohtani University, Osaka, Japan","institution_ids":["https://openalex.org/I167598709"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5025034965","display_name":"Masaya Takahashi","orcid":"https://orcid.org/0000-0003-2649-4638","observed_orcids":["https://orcid.org/0000-0003-2649-4638"]},"institutions":[{"id":"https://openalex.org/I4387152983","display_name":"Osaka Metropolitan University","ror":"https://ror.org/01hvx5h04","country_code":"JP","type":"education","lineage":["https://openalex.org/I4387152983"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"MASAYA TAKAHASHI","raw_affiliation_strings":["Department of Pharmacy, Osaka Metropolitan University Hospital, Osaka, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pharmacy, Osaka Metropolitan University Hospital, Osaka, Japan","institution_ids":["https://openalex.org/I4387152983"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5088072534","display_name":"Katsuhito Nagai","orcid":"https://orcid.org/0000-0003-0753-9861","observed_orcids":["https://orcid.org/0000-0003-0753-9861"]},"institutions":[{"id":"https://openalex.org/I167598709","display_name":"Osaka Ohtani University","ror":"https://ror.org/01jtn9895","country_code":"JP","type":"education","lineage":["https://openalex.org/I167598709"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"KATSUHITO NAGAI","raw_affiliation_strings":["Faculty of Pharmacy, Osaka Ohtani University, Osaka, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Faculty of Pharmacy, Osaka Ohtani University, Osaka, Japan","institution_ids":["https://openalex.org/I167598709"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5023611724","display_name":"Sachiko Omotani","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I167598709","display_name":"Osaka Ohtani University","ror":"https://ror.org/01jtn9895","country_code":"JP","type":"education","lineage":["https://openalex.org/I167598709"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"SACHIKO OMOTANI","raw_affiliation_strings":["Faculty of Pharmacy, Osaka Ohtani University, Osaka, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Faculty of Pharmacy, Osaka Ohtani University, Osaka, Japan","institution_ids":["https://openalex.org/I167598709"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072956858","display_name":"Mayu Nakahara","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I167598709","display_name":"Osaka Ohtani University","ror":"https://ror.org/01jtn9895","country_code":"JP","type":"education","lineage":["https://openalex.org/I167598709"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"MAYU NAKAHARA","raw_affiliation_strings":["Faculty of Pharmacy, Osaka Ohtani University, Osaka, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Faculty of Pharmacy, Osaka Ohtani University, Osaka, Japan","institution_ids":["https://openalex.org/I167598709"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5058359478","display_name":"Shuhei Fukuno","orcid":"https://orcid.org/0000-0002-8125-2589","observed_orcids":["https://orcid.org/0000-0002-8125-2589"]},"institutions":[{"id":"https://openalex.org/I167598709","display_name":"Osaka Ohtani University","ror":"https://ror.org/01jtn9895","country_code":"JP","type":"education","lineage":["https://openalex.org/I167598709"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"SHUHEI FUKUNO","raw_affiliation_strings":["Faculty of Pharmacy, Osaka Ohtani University, Osaka, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Faculty of Pharmacy, Osaka Ohtani University, Osaka, Japan","institution_ids":["https://openalex.org/I167598709"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5134778614","display_name":"Yuichiro Hori","orcid":"https://orcid.org/0009-0005-0044-4722","observed_orcids":["https://orcid.org/0009-0005-0044-4722"]},"institutions":[{"id":"https://openalex.org/I167598709","display_name":"Osaka Ohtani University","ror":"https://ror.org/01jtn9895","country_code":"JP","type":"education","lineage":["https://openalex.org/I167598709"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"YUICHIRO HORI","raw_affiliation_strings":["Faculty of Pharmacy, Osaka Ohtani University, Osaka, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Faculty of Pharmacy, Osaka Ohtani University, Osaka, Japan","institution_ids":["https://openalex.org/I167598709"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5052694327","display_name":"Yasutaka Nakamura","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4387152983","display_name":"Osaka Metropolitan University","ror":"https://ror.org/01hvx5h04","country_code":"JP","type":"education","lineage":["https://openalex.org/I4387152983"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"YASUTAKA NAKAMURA","raw_affiliation_strings":["Department of Pharmacy, Osaka Metropolitan University Hospital, Osaka, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pharmacy, Osaka Metropolitan University Hospital, Osaka, Japan","institution_ids":["https://openalex.org/I4387152983"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5042878086","display_name":"Michiaki Myotoku","orcid":"https://orcid.org/0000-0002-7576-7287","observed_orcids":["https://orcid.org/0000-0002-7576-7287"]},"institutions":[{"id":"https://openalex.org/I167598709","display_name":"Osaka Ohtani University","ror":"https://ror.org/01jtn9895","country_code":"JP","type":"education","lineage":["https://openalex.org/I167598709"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"MICHIAKI MYOTOKU","raw_affiliation_strings":["Faculty of Pharmacy, Osaka Ohtani University, Osaka, Japan; myoutom@osaka-ohtani.ac.jp"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Faculty of Pharmacy, Osaka Ohtani University, Osaka, Japan; myoutom@osaka-ohtani.ac.jp","institution_ids":["https://openalex.org/I167598709"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.0,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"46","issue":"11","first_page":"6297","last_page":"6305"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12172","display_name":"Neutropenia and Cancer Infections","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T12172","display_name":"Neutropenia and Cancer Infections","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12919","display_name":"Blood disorders and treatments","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/proton-pump-inhibitors","display_name":"proton pump inhibitors","score":0.9869999885559082},{"id":"https://openalex.org/keywords/febrile-neutropenia","display_name":"febrile neutropenia","score":1.0},{"id":"https://openalex.org/keywords/r-chop","display_name":"R-CHOP","score":0.8799999952316284},{"id":"https://openalex.org/keywords/non-hodgkin-lymphoma","display_name":"non-Hodgkin lymphoma","score":0.9909999966621399},{"id":"https://openalex.org/keywords/chemotherapy-induced-neutropenia","display_name":"chemotherapy-induced neutropenia","score":0.7620000243186951},{"id":"https://openalex.org/keywords/risk-factors","display_name":"risk factors","score":0.781000018119812},{"id":"https://openalex.org/keywords/rituximab","display_name":"rituximab","score":0.9269999861717224},{"id":"https://openalex.org/keywords/cyclophosphamide","display_name":"cyclophosphamide","score":0.9419999718666077},{"id":"https://openalex.org/keywords/doxorubicin","display_name":"doxorubicin","score":0.9769999980926514},{"id":"https://openalex.org/keywords/vincristine","display_name":"vincristine","score":0.972000002861023},{"id":"https://openalex.org/keywords/prednisolone","display_name":"prednisolone","score":0.9959999918937683}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8723999857902527},{"id":"https://openalex.org/C17923572","wikidata":"https://www.wikidata.org/wiki/Q7250160","display_name":"Propensity score matching","level":2,"score":0.8292999863624573},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.7815999984741211},{"id":"https://openalex.org/C156957248","wikidata":"https://www.wikidata.org/wiki/Q1862216","display_name":"Odds ratio","level":2,"score":0.7013999819755554},{"id":"https://openalex.org/C44249647","wikidata":"https://www.wikidata.org/wiki/Q208498","display_name":"Confidence interval","level":2,"score":0.6123999953269958},{"id":"https://openalex.org/C2781025758","wikidata":"https://www.wikidata.org/wiki/Q421704","display_name":"Proton-pump inhibitor","level":2,"score":0.5526000261306763},{"id":"https://openalex.org/C2778850193","wikidata":"https://www.wikidata.org/wiki/Q3775974","display_name":"Febrile neutropenia","level":4,"score":0.548799991607666},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.47189998626708984},{"id":"https://openalex.org/C2777063308","wikidata":"https://www.wikidata.org/wiki/Q1435822","display_name":"Neutropenia","level":3,"score":0.44429999589920044},{"id":"https://openalex.org/C151956035","wikidata":"https://www.wikidata.org/wiki/Q1132755","display_name":"Logistic regression","level":2,"score":0.4429999887943268},{"id":"https://openalex.org/C167135981","wikidata":"https://www.wikidata.org/wiki/Q2146302","display_name":"Retrospective cohort study","level":2,"score":0.4043999910354614},{"id":"https://openalex.org/C2779338263","wikidata":"https://www.wikidata.org/wiki/Q208414","display_name":"Lymphoma","level":2,"score":0.39500001072883606},{"id":"https://openalex.org/C2781413609","wikidata":"https://www.wikidata.org/wiki/Q7308373","display_name":"Regimen","level":2,"score":0.3937000036239624},{"id":"https://openalex.org/C50440223","wikidata":"https://www.wikidata.org/wiki/Q1475848","display_name":"Risk factor","level":2,"score":0.33320000767707825},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.32910001277923584},{"id":"https://openalex.org/C2776715498","wikidata":"https://www.wikidata.org/wiki/Q11426176","display_name":"Prednisolone","level":2,"score":0.30489999055862427},{"id":"https://openalex.org/C82789193","wikidata":"https://www.wikidata.org/wiki/Q2142611","display_name":"Relative risk","level":3,"score":0.2976999878883362},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.2825999855995178},{"id":"https://openalex.org/C2779915747","wikidata":"https://www.wikidata.org/wiki/Q17058619","display_name":"Inverse probability weighting","level":3,"score":0.2825999855995178},{"id":"https://openalex.org/C2776364478","wikidata":"https://www.wikidata.org/wiki/Q467635","display_name":"Multiple myeloma","level":2,"score":0.28139999508857727},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.2632000148296356}],"mesh":[{"descriptor_ui":"D000069283","descriptor_name":"Rituximab","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000069283","descriptor_name":"Rituximab","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D003520","descriptor_name":"Cyclophosphamide","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D003520","descriptor_name":"Cyclophosphamide","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D004317","descriptor_name":"Doxorubicin","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008228","descriptor_name":"Lymphoma, Non-Hodgkin","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011241","descriptor_name":"Prednisone","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D012189","descriptor_name":"Retrospective Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012307","descriptor_name":"Risk Factors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014750","descriptor_name":"Vincristine","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D014750","descriptor_name":"Vincristine","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D054328","descriptor_name":"Proton Pump Inhibitors","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D054328","descriptor_name":"Proton Pump Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D064147","descriptor_name":"Febrile Neutropenia","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.21873/anticanres.18458","doi":"https://doi.org/10.21873/anticanres.18458","is_oa":false,"landing_page_url":"https://doi.org/10.21873/anticanres.18458","pdf_url":null,"source":{"id":"https://openalex.org/S157347057","display_name":"Anticancer Research","issn_l":"0250-7005","issn":["0250-7005","1791-7530"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-d","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-3","vabb-shw"],"host_organization":"https://openalex.org/P4320800545","host_organization_name":"International Institute of Anticancer Research (IIAR) Conferences 1997. Athens, Greece. Abstracts","host_organization_lineage":["https://openalex.org/P4320800545"],"host_organization_lineage_names":["International Institute of Anticancer Research (IIAR) Conferences 1997. Athens, Greece. Abstracts"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Anticancer Research","raw_type":"journal-article"},{"id":"pmid:42946406","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/42946406","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Anticancer research","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Observational Study","id":"https://openalex.org/study-designs/observational-study"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W3158395941","https://openalex.org/W2617630794","https://openalex.org/W2611822758","https://openalex.org/W2889811659","https://openalex.org/W2023291563","https://openalex.org/W2555439343","https://openalex.org/W2157862701","https://openalex.org/W4385667333","https://openalex.org/W320721428","https://openalex.org/W2018370326"],"abstract_inverted_index":{"Background/Aim:":[0],"Febrile":[1],"neutropenia":[2],"(FN)":[3],"is":[4],"an":[5,231],"oncologic":[6],"emergency,":[7],"making":[8],"the":[9,36,68,123,154,164,175,178,215],"identification":[10],"of":[11,38,70,133,149,159,190,209,234],"its":[12,51],"risk":[13,27,233],"factors":[14],"critical.":[15],"Proton":[16],"pump":[17],"inhibitor":[18],"(PPI)":[19],"use":[20,40,72,183,226],"has":[21],"recently":[22],"been":[23],"reported":[24],"as":[25],"a":[26,84,204],"factor":[28],"for":[29,94],"FN.":[30,144],"However,":[31],"no":[32],"studies":[33],"have":[34],"evaluated":[35],"impact":[37,52,69],"PPI":[39,71,155,182,212,225],"on":[41,73],"FN":[42,74,145,191,210,235],"by":[43],"individual":[44],"chemotherapy":[45],"regimen":[46],"in":[47,147,153,163,174,236],"malignant":[48],"lymphoma,":[49],"and":[50,58,79,157],"during":[53,75],"rituximab,":[54],"cyclophosphamide,":[55],"doxorubicin,":[56],"vincristine,":[57],"prednisolone":[59],"(R-CHOP)":[60],"therapy":[61,93],"remains":[62],"unclear.":[63],"Therefore,":[64],"this":[65],"study":[66,82,87],"examined":[67],"R-CHOP":[76,92,241],"therapy.":[77,242],"Patients":[78],"Methods:":[80],"This":[81],"was":[83,128,184,217],"single-center":[85],"retrospective":[86],"including":[88],"patients":[89,151,161,237],"who":[90],"received":[91],"non-Hodgkin":[95],"lymphoma":[96],"(NHL)":[97],"at":[98],"Osaka":[99],"Metropolitan":[100],"University":[101],"Hospital":[102],"from":[103],"January":[104],"2012":[105],"to":[106],"December":[107],"2022.":[108],"The":[109,200],"primary":[110],"analysis":[111,202],"used":[112],"conditional":[113],"logistic":[114,126],"regression":[115,127],"after":[116],"1:1":[117],"propensity":[118,179],"score":[119],"matching":[120],"(PSM).":[121],"For":[122],"sensitivity":[124],"analysis,":[125,181],"performed":[129],"using":[130],"inverse":[131],"probability":[132],"treatment":[134],"weighting":[135],"(IPTW).":[136],"Results:":[137],"Among":[138],"163":[139],"patients,":[140],"25":[141],"(15.3%)":[142],"developed":[143],"occurred":[146],"18":[148],"85":[150],"(21.2%)":[152],"group":[156],"7":[158],"78":[160],"(9.0%)":[162],"non-PPI":[165],"group.":[166],"After":[167],"PSM,":[168],"58":[169],"matched":[170],"pairs":[171],"were":[172],"included":[173],"analysis.":[176],"In":[177],"score-matched":[180],"associated":[185,229],"with":[186,211,230,238],"significantly":[187],"higher":[188,207],"odds":[189,208],"[odds":[192],"ratio":[193],"(OR)=6.50;":[194],"95%":[195],"confidence":[196],"interval":[197],"(CI)=1.47-28.8;":[198],"p=0.014].":[199],"IPTW":[201],"showed":[203],"trend":[205],"toward":[206],"use,":[213],"although":[214],"difference":[216],"not":[218],"statistically":[219],"significant":[220],"(OR=2.40;":[221],"95%CI=0.89-6.48;":[222],"p=0.084).":[223],"Conclusion:":[224],"may":[227],"be":[228],"increased":[232],"NHL":[239],"receiving":[240]},"counts_by_year":[],"updated_date":"2026-10-29T09:56:32.521200","created_date":"2026-10-28T00:00:00"}